155 related articles for article (PubMed ID: 36170959)
1. Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia.
Mau LW; Preussler JM; Meyer CL; Senneka MK; Wallerstedt S; Steinert P; Khera N; Saber W
Transplant Cell Ther; 2022 Dec; 28(12):852-858. PubMed ID: 36170959
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
[TBL] [Abstract][Full Text] [Related]
3. Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia.
Mau LW; Meyer C; Burns LJ; Saber W; Steinert P; Vanness DJ; Preussler JM; Silver A; Leppke S; Murphy EA; Denzen E
JNCI Cancer Spectr; 2019 Dec; 3(4):pkz048. PubMed ID: 31750417
[TBL] [Abstract][Full Text] [Related]
4. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
Tokaz MC; Baldomero H; Cowan AJ; Saber W; Greinix H; Koh MBC; Kröger N; Mohty M; Galeano S; Okamoto S; Chaudhri N; Karduss AJ; Ciceri F; Colturato VAR; Corbacioglu S; Elhaddad A; Force LM; Frutos C; León AG; Hamad N; Hamerschlak N; He N; Ho A; Huang XJ; Jacobs B; Kim HJ; Iida M; Lehmann L; de Latour RP; Percival MM; Perdomo M; Rasheed W; Schultz KR; Seber A; Ko BS; Simione AJ; Srivastava A; Szer J; Wood WA; Kodera Y; Nagler A; Snowden JA; Weisdorf D; Passweg J; Pasquini MC; Sureda A; Atsuta Y; Aljurf M; Niederwieser D
Transplant Cell Ther; 2023 Apr; 29(4):279.e1-279.e10. PubMed ID: 36572384
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.
Arnold SD; Brazauskas R; He N; Li Y; Hall M; Atsuta Y; Dalal J; Hahn T; Khera N; Bonfim C; Hashmi S; Parsons S; Wood WA; Steinberg A; Freytes CO; Dandoy CE; Marks DI; Lazarus HM; Abdel-Azim H; Bitan M; Diaz MA; Olsson RF; Gergis U; Seber A; Wirk B; LeMaistre CF; Ustun C; Duncan C; Rizzieri D; Szwajcer D; Fagioli F; Frangoul H; Knight JM; Kamble RT; Mehta P; Schears R; Satwani P; Pulsipher MA; Aplenc R; Saber W
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1747-1756. PubMed ID: 32464284
[TBL] [Abstract][Full Text] [Related]
6. Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States.
Yao S; Hahn T; Zhang Y; Haven D; Senneka M; Dunford L; Parsons S; Confer D; McCarthy PL
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1459-64. PubMed ID: 23811537
[TBL] [Abstract][Full Text] [Related]
7. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.
Hahn T; McCarthy PL; Hassebroek A; Bredeson C; Gajewski JL; Hale GA; Isola LM; Lazarus HM; Lee SJ; Lemaistre CF; Loberiza F; Maziarz RT; Rizzo JD; Joffe S; Parsons S; Majhail NS
J Clin Oncol; 2013 Jul; 31(19):2437-49. PubMed ID: 23715573
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Administrative Claims Data: Feasibility, Validation and Application of Linking Medicare Claims Data and National Marrow Donor Program Search Data.
Preussler JM; Meyer CL; Sees Coles JA; Yoo D; Mau LW; Garrett ND; Auletta JJ
JCO Clin Cancer Inform; 2022 Oct; 6():e2200069. PubMed ID: 36228178
[TBL] [Abstract][Full Text] [Related]
9. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.
Abid MB; Estrada-Merly N; Zhang MJ; Chen K; Allan D; Bredeson C; Sabloff M; Guru Murthy GS; Badar T; Hashmi S; Aljurf M; Litzow MR; Kebriaei P; Hourigan CS; Saber W
Transplant Cell Ther; 2023 Sep; 29(9):578.e1-578.e9. PubMed ID: 37406882
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
Ustun C; Le-Rademacher J; Wang HL; Othus M; Sun Z; Major B; Zhang MJ; Storrick E; Lafky JM; Chow S; Mrózek K; Attar EC; Nand S; Bloomfield CD; Cripe LD; Tallman MS; Appelbaum F; Larson RA; Marcucci G; Roboz GJ; Uy GL; Stone RM; Jatoi A; Shea TC; de Lima M; Foran JM; Sandmaier BM; Litzow MR; Erba HP; Hurria A; Weisdorf DJ; Artz AS
Leukemia; 2019 Nov; 33(11):2599-2609. PubMed ID: 31073153
[TBL] [Abstract][Full Text] [Related]
12. Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis.
Paulson K; Brazauskas R; Khera N; He N; Majhail N; Akpek G; Aljurf M; Buchbinder D; Burns L; Beattie S; Freytes C; Garcia A; Gajewski J; Hahn T; Knight J; LeMaistre C; Lazarus H; Szwajcer D; Seftel M; Wirk B; Wood W; Saber W
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2086-2090. PubMed ID: 31228584
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
14. Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia.
Chen GL; Liu H; Zhang Y; Thomas J; Ross M; Wang ES; Block AW; Sait S; Deeb G; Wallace P; Wetzler M; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1369-74. PubMed ID: 24867777
[TBL] [Abstract][Full Text] [Related]
15. Timing and Utility of Relapse Surveillance after Allogeneic Hematopoietic Cell Transplantation in Children with Leukemia.
Levinson A; Arnold S; Jin Z; Bhatia M; George D; Garvin JH; Satwani P
Biol Blood Marrow Transplant; 2017 Apr; 23(4):696-700. PubMed ID: 28063963
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Aldoss I; Tsai NC; Slovak ML; Palmer J; Alvarnas J; Marcucci G; Forman SJ; Pullarkat V
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1212-1217. PubMed ID: 27044907
[TBL] [Abstract][Full Text] [Related]
17. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Sandhu KS; Dadwal S; Yang D; Mei M; Palmer J; Salhotra A; Al Malki M; Aribi A; Ali H; Khaled S; Forman SJ; Snyder D; Nakamura R; Stein AS; Marcucci G; Aldoss I; Pullarkat V
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e322-e327. PubMed ID: 32866594
[TBL] [Abstract][Full Text] [Related]
20. Barriers to Access to Hematopoietic Cell Transplantation among Patients with Acute Myeloid Leukemia in Virginia.
Mock J; Meyer C; Mau LW; Nguyen C; Arora P; Heron C; Balkrishnan R; Burns L; Devine S; Ballen K
Transplant Cell Ther; 2021 Oct; 27(10):869.e1-869.e9. PubMed ID: 34224915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
